

Industry: Medical device

Management:

Ilya Popov, MBA - Founder, CEO
Nataliia Popova - Hardware Executive

Advisory Board:

Mark Viscogliosi, MD, *Principal at Viscogliosi Bros VC, Chairman & CEO at Spine BioPharma*
Vadim Gordin, *Director - NYU Future Labs A/X Venture Studio*
Eziah Syed, *founder at MEND.ME 5 years in rehab nutrition supplying*

Scientific Advisory Board:

Andrew Fang, MD, *Chief of Orthopaedic Surgery at Kaiser Permanente*
Pishtiwan Kalmet, MD, PhD, *Trauma Surgeon, 17 research in "Weight-Bearing"*
Rohit Hasija, MD, *Board Clinical Physician at NYC H/H Elmhurst Hospital*

Employers & contractors: 8

Financing to date: \$2,141,600

- Institutional investor: \$491,5k
- Government grant: \$75k
- Google support grant: \$50k
- UA angels: \$550k
- US angels: \$163k
- Team: \$192,1k
- ZAS Ventures: \$500k
- TechStars \$120k

Requested Funding: \$300k

Use of funds:

- finish clinical research;
- obtain device use reimbursement;
- commercialization with existing partners/providers.

Legal: Ayzenberg Consulting LLC

IP: Adapt IP Law

Ilya Popov

Cell: 312-927-4108
ceo@comebackmobility.com
<https://comebackmobility.com>

Business Description / Company Background:

ComeBack Mobility has developed mobile apps that allow doctors to design weight-bearing rehab programs after lower limb injuries and biofeedback [Smart Crutch Tips](#) IoT devices for at-home patient compliance. It reduces complications and revision surgeries, expedites recovery, and improves bone healing, generating additional revenue for practices and savings for payers.

Founded in 2020, we aim to fill a gap in postoperative rehabilitation by offering objective, measurable loading protocols that patients can easily follow. Our journey began with the founder's postoperative experience, which led to the development of convenient, reusable devices that have already helped 200+ patients. This resulted in new technology-driven protocols, the effectiveness of which is currently being proven in studies with top US hospitals.

Market Opportunity / Unmet Need:

Over 211 M lower limb injuries worldwide require weight-bearing protocols annually. In the US alone, there are 4.8M such cases, including 3.4M fractures, which are our current focus. US insurance companies lose \$15B on fracture postoperative complications, a third of which we aim to save.

Products/Services – Launched & Pipeline:

Launched: Our current product is the patient biofeedback device and a digital component for doctors that designs personalized weight-bearing protocols based on CT scans for optimized rehabilitation.

Pipeline: We are collecting patients' rehab activity data and using AI to find the best approach for improving standards of care after lower limb injuries.

Commercial / Technical Milestones:

Achieved: Produced an industrial batch of 200 pairs of devices and software. Inspected and obtained FDA Form 482, FCC Grant, QMS 9001 and 27001 certifications, and HIPAA compliance. Device, system, method, and step detection have been patented and trademarks registered. Conducted and published a [validation study](#) and successfully completed a patient [satisfaction study](#).

Pending: Developed a new approach for postsurgical weight-bearing protocols and established partnerships with NYU Langone (Q3 2023), Kaiser Permanente (Q4 2023), JPS (Q4 2023), and other level-one trauma hospitals to prove significant improvements in recovery time, bone healing, internal fixation failure, residual pain, QoL, and other patient outcomes. Initiated discussions with major insurance companies about pilot programs showcasing cost-saving benefits and clinical efficacy to obtain device use reimbursement (Q3 2025). Sales restarts (Q4 2025).

Competition / Competitive Advantages / Customer Benefits:

Competing solutions: [SmartStep](#), [OpenGo](#) & [SensiStep](#) utilize weight sensors integrated into sandals or insoles. However, these options are often costly and need more reusability. In contrast, our solution offers superior value as it is reusable, cost-effective to manufacture, and has already been successfully deployed in the market.

Financial Forecast (Unaudited):

	2021	2022	2023	2024	2025	2026
Revenue (\$k)	3	0	0	0	80	1800
Growth Rate	NMF	0	0	0	NMF	2100%
Gross Profit (\$k)	-334	0	0	0	78	1764
Gross Margin	-11133%	0	0	0	93%	98%